Clb2 is the major B-type mitotic cyclin required for entry into mitosis in the budding yeast Saccharomyces cerevisiae. We showed that accumulation of CLB2 transcripts in G 2 cells is controlled at the transcriptional level and identified a 55-bp upstream activating sequence (UAS) containing an Mcm1 binding site as being necessary and sufficient for cell cycle regulation. Sequences within the cell cycle-regulated UAS were shown to bind Mcm1 in vitro, and mutations which abolished Mcm1-dependent DNA binding activity eliminated cell cycle-regulated transcription in vivo. A second protein with no autonomous DNA binding activity was also recruited into Mcm1-UAS complexes, generating a ternary complex. A point mutation in the CLB2 UAS which blocked ternary complex formation, but still allowed Mcm1 to bind, resulted in loss of cell cycle regulation in vivo, suggesting that the ternary complex factor is also important in control of CLB2 transcription. We discuss the possibility that the CLB2 gene is coregulated with other genes known to be regulated with the same periodicity and suggest that Mcm1 and the ternary complex factor may coordinately regulate several other G 2 -regulated transcripts.
In the budding yeast Saccharomyces cerevisiae, the CDC28 gene encodes a 34-kDa protein (p34
CDC28
) which serves as the catalytic subunit for a cell cycle-regulated protein kinase. This kinase regulates the G 2 -M transition, and passage through a control point in G 1 known as Start, where cells prepare for DNA replication and become irreversibly committed to a further round of cell division. Changes in p34
-dependent kinase activity during the cell cycle are controlled by posttranslational modifications and by its assembly into a protein complex with regulatory subunits known as cyclins. These proteins are so named after their cyclic accumulation and degradation during the cell cycle.
In the G 1 phase, Cdc28 complexes with one of three functionally redundant G 1 cyclins (Cln1, Cln2, or Cln3), which together are required for execution of Start and for the G 1 -to-S transition. Regulation of the G 2 -M transition by p34 CDC28 requires its assembly into a complex with a separate group of cyclins known as mitotic B-type cyclins. Four mitotic B-type cyclins have been identified in S. cerevisiae: CLB1, CLB2, CLB3 and CLB4 (10, 11, 23, 28) . Clb1 and Clb2 are closely related to one another and to Cdc13, a cyclin B protein essential for mitosis in Schizosaccharomyces pombe, whereas Clb3 and Clb4 more closely resemble the S. pombe B-type cyclin homolog cig1 (23) . None of the mitotic cyclins in S. cerevisiae by themselves are essential for viability as they are, at least to some extent, functionally redundant (10, 11, 23, 28) . Clb2, however, appears to be the most important B-type cyclin for initiation and completion of mitosis (10, 11, 28) and appears to be important in processes such as spindle elongation (17, 28) and negative regulation of bud emergence (5, 17) .
In contrast to CLB3 and CLB4 transcripts, which increase early in the S phase, CLB1 and CLB2 transcripts begin to accumulate late in S phase and remain elevated until late in mitosis (10, 11, 23, 28) . Increased levels of CLB2 transcripts at this time correlate with Clb2-associated kinase activity, which peaks just before and disappears immediately following anaphase (27) . These observations suggest that CLB2 mRNA levels play an important role in control of Clb2 activity. It is not known, however, if levels of mitotic cyclins are controlled at the transcriptional or posttranscriptional level. Several other genes, such as CLB1, CDC5, ACE2, and SWI5, are expressed at the same time in the cell cycle as CLB2 (8, 16, 28) , raising the possibility that these genes are coregulated. Our understanding of G 2 -specific transcription, however, is based exclusively on studies of the SWI5 gene. Regulation of SWI5 transcription is dependent on a cell cycle-regulated upstream activation sequence (UAS) which binds the Mcm1 transcription factor and a second protein, the SWI5 factor (SFF), which binds only as part of a ternary complex with Mcm1 (18) . This is similar to the recruitment of ternary complex factors by the mammalian counterpart of Mcm1, the serum response factor SRF (7, 29) . Through its interactions with cell type-specific coactivators and corepressors, Mcm1 also regulates genes not under cell cycle control, such as cell type-specific pheromone and receptor genes. It is therefore likely that Mcm1 has no intrinsic cell cycle-regulated activity and that the regulatory component of the SWI5 transcription complex is provided by SFF.
This report concerns the mechanism which controls CLB2 expression during the cell cycle. We show that CLB2 transcription plays a major part in the control of CLB2 mRNA levels in the cell cycle. Furthermore, we identified a UAS from the CLB2 promoter that is necessary and sufficient for cell cycle control and requires the Mcm1 transcription factor together with an associated ternary complex factor for activity. We discuss the possibility that this transcription factor complex functions in the coregulation of other genes expressed late in the cell cycle.
MATERIALS AND METHODS
Yeast strains and media. Cells were routinely grown at 30ЊC in YEPD medium (1% yeast extract, 2% Bacto Peptone, 0.1 mg of adenine per ml, 2% glucose). All other yeast manipulations were done as described previously (7) . The yeast strains used in this study are listed in Table 1 .
Deletion analysis of the CLB2 promoter. A CLB2 promoter fragment beginning at the ATG initiator methionine and extending to position Ϫ2,992 was generated by PCR and subcloned into pLG⌬-178 (13) as a SalI-BamHI fragment (sites introduced by PCR); this generated a fusion between the CLB2 5Ј-flanking region and the lacZ gene, which reads 5Ј-ATC.TTATAG.ATG.ACC.GGA.TC C.GGA.GCT.TGG-lacZ-3Ј at the junction (initiator ATG in boldface, BamHI site underlined). The PCR-generated CLB2 portion of this construct was replaced with an internal XbaI-NheI CLB2 restriction fragment from pCLB2/5.5 (pBS.KSϩ with a 5.5-kb BamHI genomic insert containing the CLB2 gene) to eliminate possible PCR errors (P330); regions at each end not replaced by this step were sequenced to confirm the absence of mutations. The CLB2 promoterlacZ fusion gene was inserted into pRS316 (25) by transferring the Ϫ2,992 CLB2-lacZ fusion gene across from P330 as a HindIII-NcoI fragment blunted with T4 DNA polymerase; this construct (P523) then served as a template to generate all of the other promoter truncations described in this report (for a summary, see Fig. 3 ). Internal deletions of the CLB2 promoter were generated by linearization of P523 with NheI, digestion with Bal 31 exonuclease (BioLabs), and recircularization. All deletions were sequenced on both strands to determine endpoints. Transcription start sites in the CLB2 promoter were determined by primer extension analysis as described previously (6) , with poly(A) ϩ RNA from S129.
Yeast reporter genes and indicator strains. For analysis of UAS sequences defined from deletion analysis of the CLB2 promoter, fragments were cloned upstream of a ubiYlacZ reporter which expresses ␤-galactosidase (␤-gal) activity with a half-life of 10 min instead of Ͼ20 h (3). All CLB2 UAS -ubiYlacZ reporter genes were initially constructed in pDL1460 as previously described (18) . Reporter genes were excised with XhoI-NcoI, blunted with T4 DNA polymerase, inserted into the StuI site of pUC.Ura3, and integrated at the URA3 locus by homologous recombination as described previously (7) . All integration events were confirmed by Southern blot analysis. Liquid culture determination of yeast ␤-gal has been described previously (7) .
Cell synchrony experiments and Northern (RNA) analysis. ␣-Factor synchronization was performed by growing 1 liter of the appropriate bar Ϫ strain in YEPD at 30ЊC to 10 7 cells per ml. ␣-Factor (from Ed Heimer, Hoffmann-La Roche Inc., Nutley, N.J.) was added to 0.1 g/ml (3 to 5 g/ml for BAR ϩ cells), and 2 h later the cells were washed twice with 200 ml of fresh YEPD and resuspended in 1 part fresh YEPD to 1 part conditioned YEPD medium (made by growing W303 1a [BAR ϩ strain] to 2 ϫ 10 7 cells per ml and using a filtrate as conditioned medium). Cell synchrony and release from ␣-factor arrest were routinely monitored by ␤-tubulin staining of mitotic spindles. Total yeast RNA was prepared by a modification of the bead-beat method (10) . RNA samples (20 g) were electrophoresed in 1% agarose-formaldehyde gels, transferred by capillary action onto Amersham Hybond hybridization filter membranes, and fixed onto filters with UV light by using a Stratalinker (Stratagene). Filters were prehybridized for at least 12 h at 42ЊC in 50% formamide-5ϫ Denhardt's solution-6ϫ SSPE (1ϫ SSPE is 0.18 M NaCl, 10 mM NaH 2 PO 4 , and 1 mM EDTA [pH 7.7])-1% sodium dodecyl sulfate-100 g of boiled, sonicated salmon sperm DNA per ml and probed in prehybridization buffer with a radioactive probe (random primed) at 10 ng/ml (specific activity, Ͼ10 9 cpm/g of DNA). The gel-isolated DNA fragments used to generate probes were CLB2 (1.3-kb internal fragment of the CLB2 gene generated by PCR), lacZ (first 350 bp of the lacZ gene in pLG⌬-178 generated by PCR), H2A/Prtl (2.3-kb SacI fragment from YpTRT1 [20] ), and URA3 (1.1-kb HindIII fragment from pUC.Ura3 [7] ). Filters were washed to final stringency with 0.2ϫ SSC (1ϫ SSC is 0.15 M NaCl plus 0.015 M sodium citrate)-0.1% sodium dodecyl sulfate at 60ЊC for 60 min. Quantitation of signals on filters after probing was performed with a Molecular Dynamics Phosphorimager.
Other techniques. Protein extracts, mobility shift gels, and synthesis of radioactive DNA probes were prepared as described previously (18) . Full-length Mcm1 (amino acids 1 to 286) was produced in Sf9 cells (19) by expression from a recombinant baculovirus vector (rBV; details to be described elsewhere). Q-Sepharose (Pharmacia) chromatography was performed by loading of crude S130 extract in PB50 (50 mM KCl, 20% glycerol, 20 mM HEPES [N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid] (pH 8.0), 5 mM EDTA, 1 mM dithiothreitol [DTT], protease inhibitors) and then stepwise elution of bound proteins with PB300 and PB1000. A protocol described previously (14) was used to raise polyclonal antibodies in rabbits against a synthetic peptide corresponding to amino acids 139 to 155 of Mcm1. Gel mobility supershift and peptide competition experiments were performed essentially as previously described (14) .
Nucleotide sequence accession number. The sequence extending to position Ϫ2,992 has been deposited in the GenBank database under accession number U14728.
RESULTS
The CLB2 5-flanking region and mapping of 5 ends of CLB2 transcripts. We sequenced the CLB2 promoter region (Fig. 1A) and determined the major transcription start sites by primer extension analysis (Fig. 1B) . The major transcription start sites mapped by this method were the same regardless of the primer used for extensions. Although the 5Ј untranslated region is unusually long (362 nucleotides for transcripts generated from the major start site), no introns were found in this region and the ATG defining the initiator methionine is the first in the CLB2 transcript. Long 5Ј untranslated leader sequences (Ͼ200 nucleotides) have been previously reported for other cell cycle-regulated transcripts (20) . The first 889 bases of this sequence are shown.
5-flanking sequences are required for cyclic accumulation of CLB2 transcripts. CLB2 mRNA levels increase late in the S phase, reach maximum levels late in G 2 , and decline rapidly as cells complete mitosis (10, 23, 28) . To determine if 5Ј-flanking sequences are required for periodic accumulation of CLB2 transcripts, we constructed a CLB2 promoter-lacZ fusion gene and integrated it at the URA3 locus. Cells were synchronized with ␣-factor, RNA levels were analyzed by Northern blot analysis, and progression through the cell cycle was monitored by assessing mitotic spindle formation. This analysis showed that lacZ transcripts from the CLB2-lacZ gene were regulated with kinetics almost indistinguishable from those of the endogenous CLB2 gene (Fig. 2) , indicating that cyclic regulation requires a promoter-5Ј untranslated region. Transcription start sites used in the CLB2-lacZ fusion were shown to be the same as in the natural CLB2 gene (data not shown). This analysis does not distinguish between transcriptional control and the possibility that the long 5Ј untranslated region plays a role in influencing transcript stability.
A 55-bp UAS is sufficient for cell cycle-regulated transcription. To identify regulatory sequences within the CLB2 promoter, we constructed a series of deletions and assayed pro- moter function by measuring ␤-gal activities from CLB2 promoter-lacZ fusion genes. This analysis defined a region from positions Ϫ362 to Ϫ131 as being important for CLB2 promoter activity (Fig. 3) . Deletion of these sequences resulted in reduction of ␤-gal activity to 11% of the wild-type level ( Fig.  3 ) and loss of cell cycle regulation (data not shown). Sequences essential for cell cycle regulation therefore lie within the Ϫ362 to Ϫ131 region. Smaller deletions within this region also resulted in substantial decreases in promoter activity but to a lesser extent than the Ϫ362 to Ϫ131 deletion ( Fig. 3 ), suggesting that multiple elements within this region contribute to the overall control of CLB2 transcription.
To test if sequences defined in the previous experiment are sufficient and necessary for cell cycle regulation of CLB2 transcription, we inserted a 232-bp fragment corresponding to the Ϫ362 to Ϫ131 region of the CLB2 promoter upstream of a ubiYlacZ gene (half-life of ␤-gal, Ͻ10 min [3] ) and integrated the gene fusion at the URA3 locus. If the CLB2 UAS is involved in cell cycle regulation of the CLB2 promoter, it should be capable of conferring such regulation on a reporter gene in a heterologous promoter environment. To address this question, cells were synchronized with ␣-factor and transcript levels were determined by Northern blot analysis. This analysis showed that ubiYlacZ transcript levels were cell cycle regulated in a pattern indistinguishable from that of endogenous CLB2 transcripts (Fig. 4B) , indicating that the Ϫ362 to Ϫ131 promoter fragment could function as a cell cycle-regulated UAS. This corresponds to a region in the CLB2 promoter which contains three sequences predicted to bind Mcm1 ( Mapping of the 5Ј termini of CLB2 transcripts. Primer extension analysis using three primers on 2 g of poly(A) ϩ RNA prepared from S129. Lanes: M, sequencing ladder markers; 1, 2, and 3, primer extension products generated by using primers which anneal on the CLB2 transcript from positions Ϫ182, Ϫ76, and Ϫ125, respectively. Several other primers which primed closer to the ATG were used in separate reactions (data not shown). In all cases, the same 5Ј CLB2 transcript termini were identified. For primer extension products in lane 3, the major transcription start site (ϩ1) is indicated by an arrow; other start sites are indicated by asterisks. The numbers on the left are marker sizes (in bases). 5A ) was inserted upstream of a ubiYlacZ gene, which was then integrated at the URA3 locus. Figure 5 shows that these sequences are sufficient to drive cell cycle-regulated transcription in a pattern indistinguishable from that of endogenous CLB2 transcripts. This element therefore functions as a cell cycleregulated UAS in vivo.
We specifically mutated sequences within the Ϫ322 Mcm1 site to determine its role in the CLB2 UAS. Both the T mutation at Ϫ317 (Ϫ317T; a G-to-T change) and Ϫ318C (a Gto-C change) in this UAS, which would be expected to significantly impair the ability of Mcm1 to bind, completely abolished cell cycle control of ubiYlacZ transcripts. Although other Mcm1 sites (positions Ϫ175 and Ϫ194) were identified in the Ϫ362 to Ϫ199 UAS (Fig. 4A ), they were dispensable for correct regulation (Fig. 5) . However, in the context of the entire promoter, these Mcm1 binding sites appear to be functionally redundant (our unpublished observations; see Discussion).
Mcm1 also plays an important role in control of SWI5 transcription (18) . Promoter sequences necessary and sufficient for cell cycle control of SWI5 consist of an Mcm1 binding site and juxtaposing sequences that are required for the recruitment of a second transcription factor, SFF (18) . As SWI5 is transcribed at the same time in the cell cycle as CLB2, and as Mcm1 is implicated in the control of both genes, this raised the possibility that both genes are under control of the same regulators. To determine if these genes share other cis-regulatory elements besides an Mcm1 binding site, we compared the SWI5 and CLB2 UAS elements to determine if any other similarities exist. Alignment of the two UAS elements revealed significant sequence similarities to the 3Ј side of the Mcm1 site which coincide with sequences known to be important in the SWI5 promoter (Fig. 5A) . A C residue at position Ϫ296 of the SWI5 promoter has previously been shown to be important in the regulation of this gene by making base-specific contacts with the SFF transcription factor (18) . As this residue and surrounding sequences are conserved in the CLB2 UAS, we decided to test the effect of introducing multiple-and single-point mutations at these positions (Fig. 5A) . Northern blot analysis revealed that the Ϫ306A mutation and the Ϫ307G/Ϫ306T/ Ϫ305G triple UAS mutation severely reduced transcription of the ubiYlacZ reporter gene and appeared to result in loss of cell cycle control (Fig. 5B and C) . At least two separate cis- [3] ) and the strong, constitutive transcriptional activation domain of the herpes simplex virus Vp16 protein, which when fused to a heterologous DNA binding domain, activates transcription if recruited to a binding site (7) . Cells were arrested by the cdc34 temperature-sensitive mutant (late G 1 ) or by the cell cycle inhibitor ␣-factor (G 1 ) or nocodazole (metaphase), and one-half of the culture was induced with galactose to promote expression of the Mcm1-Vp16 fusion. In cycling cells and nocodazole-blocked cells, where CLB2 transcription is on, ␤-gal activity was considerably higher than in ␣-factor-or cdc34-blocked cells, where CLB2 transcription is normally off (Fig. 6) . Expression of Mcm1-Vp16 significantly increased ␤-gal activity in all cultures but was most pronounced in ␣-factor-and cdc34-blocked cells, . Cells were originally grown in YEPD medium plus 2% raffinose (Raff) and, when appropriate, arrested under restrictive conditions (at 37ЊC or in the presence of a cell cycle inhibitor [0.2 g of ␣-factor per ml or 150 g of nocodazole per ml]) and split in two, at which time expression of the Mcm1-Vp16 fusion was induced in one of the cultures by addition of galactose (Gal) to 2%. Extracts were prepared 120 min after the time of galactose addition. Liquid culture ␤-gal assays were performed as described in Materials and Methods.
(18; see above): the Ϫ306A point mutation and the Ϫ307G/Ϫ306T/Ϫ305G triple mutation. (C) Northern blots were tested with a Phosphorimager to quantitatively determine levels of ubiYlacZ transcripts, which are shown relative to that of the non-cell cycle control transcript, Prt1. Symbols: F, wild type; E, Ϫ318C; s, Ϫ317T; ᮀ, Ϫ307G/Ϫ306T/Ϫ305GC; å, Ϫ306A. UAS elements were inserted upstream of a ubiYlacZ reporter gene and integrated into the URA3 locus of S131 for cell cycle analysis. Cell synchrony and analysis of transcripts were done as described in the legend to Fig. 4 .
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where activity of the uninduced (cells grown in raffinose medium) culture was very low. A point mutation in the CLB2 UAS shown to severely reduce Mcm1 binding (see Fig. 7 ) also showed severely reduced ubiYlacZ activity compared with the wild-type control, showing that trans-activation by Mcm1-Vp16 is dependent on its ability to bind the UAS. In contrast, activity of the Ϫ306A mutant UAS was similar to that of the wild type. To show that this is specific for the CLB2 UAS, the same experiment was performed with a strain carrying a ubiYlacZ gene driven by the non-cell cycle-regulated RP39 UAS. In this strain, Mcm1-Vp16 failed to increase reporter gene activity, confirming that trans activation requires an intact Mcm1 binding site.
Mcm1 recruits a ternary complex factor to the CLB2 UAS in vitro.
To determine if we could detect binding of Mcm1 to the cell cycle-regulated CLB2 UAS from crude whole-cell extracts, we performed band shift experiments by using the wild-type CLB2 UAS as a probe. In this assay, we detected several specific DNA-protein complexes (Fig. 7A) , designated here T, M, and B (lanes b to m), which did not appear to vary with the cell cycle (data not shown). These protein-DNA complexes are all sensitive to mutations in the predicted Mcm1 binding site which would be expected to abolish or significantly reduce Mcm1 binding. For example, the Ϫ318C and Ϫ317T mutations which change essential DNA contact points for Mcm1 and abolish cell cycle-regulated UAS activity in vivo severely reduced or abolished formation of T, M, and B complexes in vitro (Fig. 7A, lanes c, f, i , and l, and our unpublished results). UAS mutations outside of the predicted Mcm1 binding site (Ϫ306A and Ϫ307G/Ϫ306T/Ϫ305G) which abolished cell cycle control in vivo (Fig. 5) also blocked the formation of ternary complexes in vitro (Fig. 7A, lanes d, g, j, and m, and 7B, lanes 4 and 5). Hence, a strong correlation exists between the ability of the CLB2 UAS to bind factors from crude cell extracts in vitro and its ability to function as a cell cycle-regulated UAS in vivo. To show that Mcm1 is a component of the complexes forming on the CLB2 UAS, an extract from a strain expressing only a truncated form of Mcm1 (Mcm ) was incubated with a probe. Under these conditions, the T, M, and B complexes disappeared on a wild-type UAS and were replaced by a fastermigrating complex, corresponding to truncated Mcm1, and a more slowly migrating ternary complex (Fig. 7B, lane 7) . Truncated Mcm1 showed decreased binding to the Ϫ318C mutant (Fig. 7B, lane 8) and was unable to form ternary complexes on the Ϫ306A and Ϫ307G/Ϫ306T/Ϫ305G mutant forms (Fig. 7B,  lanes 9 and 10) , which we have shown to cause loss of cell cycle control in vivo (Fig. 5) ; these results are therefore consistent with those obtained with full-length Mcm1 (Fig. 7A and B,  lanes 2 to 5) .
To characterize the binding of Mcm1 to the CLB2 UAS further, we used an rBV expression vector to produce high levels of Mcm1 (rMcm1) in insect cells. rMcm1 binding activity in crude insect cell extracts was detected by band shift analysis (Fig. 7B, lanes 11 to 15) and was similar to the DNA binding specificity of Mcm1 from crude yeast extracts (Fig. 7B , compare lanes 2 to 5 to lanes 12 to 15) but generated a protein-DNA complex with slightly higher mobility (Fig. 7B) . The same UAS point mutations which severely reduced yeast Mcm1 binding had similar effects on Mcm1 produced in insect cells. Extracts prepared from mock-infected insect cells showed no Mcm1-like binding activity in this assay (Fig. 7B, lane 11) . Importantly, we showed that binding of Mcm1 from crude cell extracts and from a recombinant source is not affected by the Ϫ306A and Ϫ307G/Ϫ306G/Ϫ305G mutations. Thus, loss of cell cycle control caused by these mutations in vivo cannot be explained by decreased Mcm1 binding.
We also showed that a protein antigenically related to Mcm1 is present in the B complex by antibody supershift experiments (Fig. 7B, lanes 16 to 23) . Antibodies raised against a peptide epitope of Mcm1 (14) specifically shifted Mcm1-dependent B complexes in band shift reactions (Fig. 7B, lanes 16 to 23) ; no shift was seen when preimmune serum was included instead of immune serum. The specificity of this antibody was shown by preincubation of the immune serum with peptides. The peptide used as an antigen to raise antibodies (14) blocked the supershift of B complexes (Fig. 7B, lane 23) , while a second peptide, which corresponds to an epitope from the Cdc45 protein (13a), failed to block the supershifting of B complexes (lane 21) under equivalent conditions. Together, these results show that the B complex is composed of an Mcm1-UAS complex and that M and T complexes must be generated by the recruitment of other proteins, in addition to Mcm1, by proteinprotein and/or protein-DNA interactions.
To formally show that factors other than Mcm1 are components of the M and T bandshift complexes, rMcm1 was incubated with protein fractions from yeast extracts depleted of Mcm1 by chromatography on a Q-Sepharose column. Mcm1-depleted extracts were then used to supplement rMcm1 in bandshift reactions as an assay for ternary complex formation. An activity collected in the low-salt flowthrough fraction (and to a lesser extent in the 0.3 M wash fraction) was found to form a ternary complex with rMcm1-DNA complexes. This activity, which we refer to as TCF CLB2 , did not bind DNA in the absence of rMcm1 (Fig. 7C, lane b) and could only be recruited to the CLB2 UAS as part of a ternary complex (Fig. 7C,  compare lanes b and g) . The mobility of the ternary complex generated by addition of the Mcm1-depleted flowthrough fraction to rMcm1 was identical to that of the T complex from crude extracts and was abolished when the Ϫ306A mutant probe was used (data not shown). We judge this activity to be the same as that detected in crude yeast extracts on the basis of these criteria. Although rMcm1-DNA complexes display greater mobility than yeast Mcm1-DNA complexes, addition of the flowthrough fraction from the Q-Sepharose column shifted rMcm1-DNA complexes to a mobility similar to that of yeast Mcm1-DNA complexes. This is probably due to association with an unidentified protein in yeast cell extracts or to extractdependent posttranslational modifications of rMcm1 (1).
Our results suggest that the CLB2 and SWI5 UAS elements are not only functionally equivalent but are controlled by the same pair of trans-acting regulators, Mcm1 and ternary complex factor (TCF)/SFF. To determine if the DNA sequence specificities for TCF-Mcm1 and SFF-Mcm1 complexes are the same or related, we performed competition binding experiments in which complexes formed on a radiolabeled CLB2 UAS were challenged by various excess amounts of the wildtype or mutant unlabeled SWI5 UAS binding site (Fig. 8) . another competitor, we used a mutant SWI5 UAS (T308) previously reported to block Mcm1-and SFF-dependent complexes through its inability to form specific base contacts with Mcm1 (18) . Little or no effect was seen when an unlabeled mutant T308 SWI5 competitor was used over a 5-to 50-fold molar excess (lanes i to k), and only partial elimination of complexes was seen at a 200-fold molar excess (lane h). The inability of this mutant binding site to compete successfully for TCF CLB2 against the CLB2 probe is reminiscent of that of the SFF factor, which also cannot bind the SWI5 site in the absence of Mcm1. A SWI5 UAS unable to bind SFF (A296; see reference 18) is predicted to be a good competitor of T, M, and B complexes which form on a CLB2 probe under these conditions as an intact Mcm1 site in such a competitor DNA would still effectively compete for Mcm1, thereby removing Mcm1-dependent ternary complexes from the CLB2 probe. These observations are consistent with the possibility that the same, or similar, proteins in cell extracts bind the CLB2 and SWI5 cell cycle-regulated UAS elements.
DISCUSSION
A role for Mcm1 and a ternary complex factor in CLB2 transcription. We have shown that cell cycle-regulated changes in levels of CLB2 transcripts are controlled at the level of transcription by demonstrating that a CLB2-lacZ fusion gene is regulated in a manner indistinguishable from that of the endogenous CLB2 gene. This periodicity is very similar to that of SWI5, CDC5, ACE2, and CLB1, which are also expressed from the late S phase through to late mitosis (8, 16, 21, 27) . A 55-bp CLB2 UAS found to be sufficient for cell cycle regulation in vivo also binds two proteins in vitro, of which we believe one is Mcm1 and the other is a ternary complex factor resembling SFF (18) . The ternary complex factor (TCF CLB2 ) identified here exhibits no autonomous DNA binding activity but is recruited into a ternary complex by DNA-bound Mcm1. Several pieces of evidence suggests that Mcm1 binds the cell cycleregulated UAS and regulates CLB2 transcription. First, a protein that displays DNA binding characteristics similar to those of Mcm1 and is antigenically related to Mcm1 binds the CLB2 UAS in vitro. Second, a strain expressing only a truncated derivative of Mcm1 forms a faster-migrating complex on gel shifts in the absence of a more slowly migrating complex seen in MCM1 wild-type strains. Third, an Mcm1-Vp16 fusion protein was capable of ectopically activating a CLB2-ubiYlacZ reporter in vivo in a sequence-specific manner. Finally, point mutations which abolished or reduced binding of Mcm1 to the CLB2 UAS in vitro had similar effects on transcription in vivo. A role for TCF CLB2 is implied by the observation that a singlebase substitution which blocked ternary complex formation in vitro also severely reduced UAS activity in vivo. We were unable to detect changes in the formation of these complexes throughout the cell cycle, and so if this complex is involved in regulating UAS activity in vivo, its involvement is probably not due to the binding activity of the components in the ternary complex alone.
Although the Ϫ362 to Ϫ131 UAS was shown to be necessary and sufficient for cell cycle control, deletion of this Mcm1 site did not abolish cell cycle control in the intact CLB2 promoter, but mutagenesis of all three Mcm1 sites in the CLB2 UAS resulted in complete loss of activity (our unpublished results). We interpreted this to mean that clustered Mcm1 sites in the CLB2 promoter are functionally redundant. It is unclear, however, if other promoter elements, such as those required for TCF CLB2 recruitment, are also functionally redundant. It is clear, though, that not all Mcm1 sites (those which bind Mcm1 in vitro) in the CLB2 UAS have closely associated sequences which are sufficient for cell cycle control (Fig. 4A) .
Evidence that Mcm1-TCF CLB2 complexes regulate multiple genes in G 2 . Mcm1 is a member of an evolutionarily conserved class of transcription factors (the MADS family [24] ) which have related DNA binding and dimerization domains. Other members of this family include a regulator of arginine biosynthesis in S. cerevisiae, Arg80 (9); the human serum response factor SRF (22) ; and the products of the plant homeotic genes deficiens (26) and agamous (31) . Mcm1 controls the expression of a group of diversely regulated genes. In MAT␣ cells, Mcm1 forms a ternary complex with the coactivator ␣1 to activate transcription of ␣-specific genes involved in determining cell identity, such as STE3 (4), and with the corepressor ␣2 to silence a-specific genes, such as STE6 (15) . In MATa cells, Mcm1 binds to the promoters of a-specific genes involved with ␣-factor responses with the Ste12 transcription factor. In each case, sequences flanking the Mcm1 binding site have an important role in recruitment of accessory factors to DNA, thus facilitating the formation of promoter-specific transcription complexes. We believe that the ternary complex factors (M and T) assembling on the CLB2 UAS are distinct from ␣1, ␣2, and STE12, as the TCF activity was detected in MATa cells (in which ␣1 and ␣2 are absent) and MAT␣ cells (Fig. 7A) and is unlikely to be Ste12, as no sequence resembling a PRTE (Ste12 binding site) was identified in the CLB2 UAS. It is likely that the M and T complexes are composed of Mcm1 and distinctly different ternary complex factors, both of which are dependent on Mcm1 for recruitment to the CLB2 UAS. The possibility that the M TCF is a breakdown product of the T TCF is unlikely, as both complexes do not appear to have the same sequence requirements (Ϫ306A mutation abolishes the T complex but not the M complex). Although mutations which abolish the T complex result in loss of cell cycle control, we know little about the role of M complexes in CLB2 control. The identification of mutants defective in M complex formation but competent to form T complexes may help address this question.
We favor the possibility that the ternary complex factor binding the CLB2 UAS in conjunction with Mcm1 is the same factor previously implicated in SWI5 regulation, SFF (18) . Several lines of evidence suggest that CLB2 transcription and SWI5 transcription are controlled by the same (or similar) regulators and that the respective UAS elements are functionally equivalent. First, both UAS elements confer cell cycle regulation with the same periodicity; second, Mcm1 is required for regulation in both cases; third, the cis regulatory sequences flanking the Mcm1 binding site in both UAS elements are very similar; and finally, both UAS elements bind at least one ternary complex factor, in addition to Mcm1, which has no detectable autonomous DNA binding activity. It is unclear if other genes expressed at the same time as CLB2 and SWI5 (such as CDC5, CLB1, and ACE2) are also under Mcm1-TCF CLB2 -SFF control. We have identified putative Mcm1 binding sites however, in the CLB1 promoter, but their functional role has not been established (our unpublished observation).
We have presented evidence which suggests that the SWI5 and CLB2 genes are coregulated by a transcription factor complex consisting of Mcm1 and a ternary complex factor, SFF-TCF CLB2 . Although molecular and biochemical characterization of SFF-TCF CLB2 has not been performed, we believe it most likely that SFF-TCF CLB2 is the target of regulation for this cell cycle-regulated transcription complex, as Mcm1 has not been previously shown to exhibit any intrinsic cell cycle regulation. We cannot, however, rule out the possibility that some other, unidentified factor is involved in periodic activation of these genes. Given the well-characterized precedent that Mcm1-regulated genes are controlled in conjunction with corepressors and coactivators, it is likely that TCF CLB2 is the regulatory subunit of the complex. This would also be similar to regulation of the SRF-elk1-TCF transcription complex which binds the serum response element in the human c-fos promoter (29) .
It has been previously suggested that the B-type mitotic cyclins are required for their own synthesis involving a positive autoregulatory loop (2) . In this report, we have demonstrated that cell cycle regulation of CLB2 mRNAs occurs at the level of transcription. Although CLB2 mRNA is unstable, its stability does not appear to be regulated with the cell cycle (6a), and so transcriptional control is most likely the only major determinant of CLB2 transcript levels. If a positive feedback loop exists, it is likely to act on CLB2 transcription via the Mcm1-TCF CLB2 transcription complex. A possible mechanism for this could involve either a direct or indirect effect of Clb-Cdc28 kinase activity on Mcm1-TCF CLB2 ; the decrease in CLB2 transcription seen at the end of mitosis could then be explained as a consequence of Clb destruction. An alternate hypothesis is that periodic transcription is governed by a repressor protein and that the ternary complex is required only for activated transcription. There is no evidence to support this model, and in SWI5 transcription, a role for a cell cycle-regulated repressor has been ruled out (18) . Moreover, a direct role for B-type cyclins in control of G 1 cyclin transcription (SCB-dependent pathway) has previously been shown (2), so it is possible that mitotic cyclins have two roles in the control of transcription in the cell cycle: repression of SCB-regulated transcripts and activation of Mcm1-TCF CLB2 -regulated transcripts in the late S and G 2 phases. We are currently investigating this possibility.
